CMB International
招银国际
CMB International (招银国际) is the investment arm of China Merchants Bank, active as both a venture capital and private equity investor alongside its banking parent. The fund appears in elsewhere's corpus primarily as a co-investor in growth-stage deals across biotech and deep-tech: it followed Sequoia China into Bota Biosciences' $100 million-plus Series B in 2021 , joined the $150 million two-round financing of AI-pharma startup METiS Pharmaceuticals in 2022 , and has been named among the first batch of institutions qualified for China's real-estate private-equity pilot as of late 2024 . Elsewhere's coverage does not include its AUM, vintage, or team structure.
AI-generated — may contain errors, please verify.
Coverage
Year-end good news: CDH Investments has raised 5 billion yuan for logistics investments.
Insurance capital is turning its attention to real estate investments.
暗涌Waves·5Y News | METiS Pharmaceuticals Closes Two Consecutive Rounds Raising $150 Million Total
Become an industry innovation leader.
五源资本·As Fierce as August | 5Y News Monthly
The big news from last month.
五源资本·5Y News | Synthetic Biology Company Bota Bio Raises Over $100 Million to Accelerate Efficient Design and Scaled Production of Bio-based Products
5Y Capital continues to pay close attention to emerging technologies at the intersection of information science and life sciences.
五源资本·5Y News | Zhuiyi Technology Secures Strategic Investment of Several Hundred Million RMB
Exploring the commercial boundaries of AI technology.
五源资本·
